Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 155Carboplatin 146Gemcitabine 140Nivolumab 135Paclitaxel 129Cisplatin 119Dexamethasone 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡